Konstantakopoulou Evgenia

Montesano Giovanni, Crabb David P, Garway-Heath David F, Wright David M, Konstantakopoulou Evgenia, Nathwani Neil et al.

First-line SLT better preserved visual fields over six years than drops in glaucoma/OHT patients. SLT should be preferred as initial treatment.

Konstantakopoulou Evgenia, Gazzard Gus, Garway-Heath David, Adeleke Mariam, Ambler Gareth, Vickerstaff Victoria et al.

Secondary SLT after 3+ years of drops reduced medication for stable glaucoma/OHT patients and lowered IOP for uncontrolled eyes, but didn't eliminate surgery. This supports SLT as a valuable secondary treatment option.

Fahy Eamonn T, Montesano Giovanni, Garg Anurag, Vickerstaff Victoria, Konstantakopoulou Evgenia, Gazzard Gus

This study found that SLT achieved greater IOP lowering than medication at higher baseline pressures, while medication performed better at lower baseline pressures, guiding initial treatment choice.

Konstantakopoulou Evgenia, Varia Jay, Parmar Janisha, Nathwani Neil, Hau Scott, Low Wing Shing et al.

A training program enabled optometrists to safely deliver SLT for glaucoma, demonstrating that non-medical professionals can expand access to this treatment with proper education.

Safitri Atika, Konstantakopoulou Evgenia, Hu Kuang, Gazzard Gus

Patients with glaucoma value both disease control (vision, independence) and treatment convenience (stable, drop-free). Future patient-reported outcome measures should reflect both aspects for better clinical assessment.

Poostchi Ali, Kastner Alan, Konstantakopoulou Evgenia, Gazzard Gus, Jayaram Hari

This review highlights the urgent need for robust, individualized glaucoma risk stratification models incorporating ocular, systemic, and progression factors to improve patient care and prevent sight loss.

Gazzard Gus, Konstantakopoulou Evgenia, Garway-Heath David, Adeleke Mariam, Vickerstaff Victoria, Ambler Gareth et al.

The LiGHT trial showed primary SLT offers better long-term glaucoma control than drops, reducing progression and need for incisional and cataract surgeries over six years, making it a safe, effective first-line option.

Konstantakopoulou Evgenia, Gazzard Gus

Konstantakopoulou Evgenia, Kastner Alan, Gazzard Gus, Jayaram Hari

This study validated the GLAUC-STRAT-fast tool, finding it effectively stratifies glaucoma risk for treatment needs and visual field loss, aiding clinical resource allocation.

Konstantakopoulou Evgenia, Jones Lee, Nathwani Neil, Gazzard Gus

Studying optometrist-delivered SLT, research found it acceptable and beneficial for the NHS, but requires standardized training, robust governance, and specific clinical prerequisites for safe implementation.

Gazzard Gus, Konstantakopoulou Evgenia, Ambler Gareth, Hunter Rachael, Vickerstaff Victoria

Wright David M, Konstantakopoulou Evgenia, Montesano Giovanni, Nathwani Neil, Garg Anurag, Garway-Heath David et al.

This study found that initial selective laser trabeculoplasty (SLT) led to less visual field progression in glaucoma/ocular hypertension patients compared to initial medical therapy, suggesting SLT may be a better first-line option.

Garg Anurag, Vickerstaff Victoria, Nathwani Neil, Garway-Heath David, Konstantakopoulou Evgenia, Ambler Gareth et al.

Repeat SLT in medication-naive glaucoma/OHT patients effectively maintains IOP control for at least 18 months, with similar duration of effect to initial treatment, offering a valuable retreatment option.

Garg Anurag, Vickerstaff Victoria, Nathwani Neil, Garway-Heath David, Konstantakopoulou Evgenia, Ambler Gareth et al.

Primary SLT for OAG/OHT showed comparable early IOP lowering to medication, achieving drop-free disease control in ~75% of eyes at 36 months, supporting its effectiveness and safety.

Gazzard Gus, Konstantakopoulou Evgenia, Garway-Heath David, Garg Anurag, Vickerstaff Victoria, Hunter Rachael et al.

This study found SLT is as effective as eye drops for first-line glaucoma/ocular hypertension treatment, with 74% needing no drops at 3 years and being more cost-effective, supporting its routine use.

Gunn Patrick J G, Marks Joanne R, Konstantakopoulou Evgenia, Edgar David F, Lawrenson John G, Roberts Stephen A et al.

This study found the Manchester Glaucoma Enhanced Referral Scheme effectively filters patients, demonstrating low false-positive (15.5%) and false-negative (0.8%) rates. This suggests efficient resource allocation and minimizes missed glaucoma cases.

Konstantakopoulou Evgenia, Gazzard Gus, Vickerstaff Victoria, Jiang Yuzhen, Nathwani Neil, Hunter Rachael et al.

The LiGHT trial compared initial SLT versus medication for glaucoma/OHT, finding baseline patient characteristics were consistent with other studies, paving the way for crucial real-world treatment efficacy and cost-effectiveness comparisons.

Gazzard Gus, Konstantakopoulou Evgenia, Garway-Heath David, Barton Keith, Wormald Richard, Morris Stephen et al.

The LiGHT trial is studying if initial selective laser trabeculoplasty (SLT) is better than eye drops for primary open-angle glaucoma/ocular hypertension, focusing on quality of life and cost-effectiveness.